MA38453B1 - Identification of a patient's response to an administration of a s1p receptor modulator - Google Patents
Identification of a patient's response to an administration of a s1p receptor modulatorInfo
- Publication number
- MA38453B1 MA38453B1 MA38453A MA38453A MA38453B1 MA 38453 B1 MA38453 B1 MA 38453B1 MA 38453 A MA38453 A MA 38453A MA 38453 A MA38453 A MA 38453A MA 38453 B1 MA38453 B1 MA 38453B1
- Authority
- MA
- Morocco
- Prior art keywords
- patient
- ethyl
- benzyloxyimino
- azetidine
- trifluoromethyl
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un procédé d'évaluation de la dose thérapeutique appropriée d'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique à administrer à un patient qui en a besoin, comprenant les étapes consistant à : (i) tester si le patient possède ou non le mauvais génotype métaboliseur; et (ii) si le patient ne possède pas le mauvais génotype métaboliseur, administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient à la dose thérapeutique habituelle; et (iii) si le patient possède le mauvais génotype métaboliseur, ou (a) administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient à une dose thérapeutique inférieure à celle de la dose thérapeutique habituelle; ou (b) ne pas administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient.The invention relates to a method for evaluating the appropriate therapeutic dose of 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine-3 -carboxylic agent to be administered to a patient in need, comprising the steps of: (i) testing whether or not the patient has the wrong metabolizing genotype; and (ii) if the patient does not have the wrong metabolizing genotype, administer 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine -3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the usual therapeutic dose; and (iii) if the patient has the wrong metabolizing genotype, or (a) administering 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose lower than that of the usual therapeutic dose; or (b) do not administer 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine-3-carboxylic acid, or a salt of it is pharmaceutically acceptable to the patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361808406P | 2013-04-04 | 2013-04-04 | |
PCT/EP2013/058226 WO2014161606A1 (en) | 2013-04-04 | 2013-04-19 | Identifying patient response to s1p receptor modulator administration |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38453A1 MA38453A1 (en) | 2016-10-31 |
MA38453B1 true MA38453B1 (en) | 2017-07-31 |
Family
ID=58501222
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38453A MA38453B1 (en) | 2013-04-04 | 2013-04-19 | Identification of a patient's response to an administration of a s1p receptor modulator |
MA40098A MA40098A1 (en) | 2013-04-04 | 2017-03-08 | Identification of a patient's response to administration of a s1p receptor modulator. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40098A MA40098A1 (en) | 2013-04-04 | 2017-03-08 | Identification of a patient's response to administration of a s1p receptor modulator. |
Country Status (1)
Country | Link |
---|---|
MA (2) | MA38453B1 (en) |
-
2013
- 2013-04-19 MA MA38453A patent/MA38453B1/en unknown
-
2017
- 2017-03-08 MA MA40098A patent/MA40098A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA38453A1 (en) | 2016-10-31 |
MA40098A1 (en) | 2018-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Janicak et al. | Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study | |
Tiseo et al. | Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee | |
Späth et al. | Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia | |
PH12015502291A1 (en) | Identifying patient response to s1p receptor modulator administration | |
Gommoll et al. | A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder | |
BR112014007357A2 (en) | therapeutic monitoring methods of nitrogen scanning drugs | |
EA200801369A1 (en) | METHODS OF TRANSDERMAL ADMINISTRATION OF THE INDONSEROTONIN RECEPTOR AGONIST AND TRANSDERMAL DOSAGE FORM FOR USE OF THIS METHOD | |
Demirel et al. | Comparison of patient‐controlled analgesia versus continuous infusion of tramadol in post‐cesarean section pain management | |
JP2017519008A5 (en) | ||
Lee et al. | Hyperprolactinemia induced by low‐dosage amisulpride in Korean psychiatric patients | |
MA40098A1 (en) | Identification of a patient's response to administration of a s1p receptor modulator. | |
Riccó et al. | Cardiovascular effects of orotracheal intubation following anesthetic induction with propofol, ketamine-propofol, or ketamine-diazepam in premedicated dogs | |
Usta et al. | Diphenhydramine use in the treatment of risperidone-induced sialorrhea | |
Collister et al. | Overexpression of copper/zinc superoxide dismutase in the median preoptic nucleus improves cardiac function after myocardial infarction in the rat | |
Schmidt et al. | P249 Effect Size Of Open-label Versus Double-blind Administration Of Tiotropium In Trials Investigating Health-related Quality Of Life In Copd | |
Thomas et al. | The impact of cannabis use on the dosage of antipsychotic drugs for patients admitted on the psychiatric ward at the University Hospital of the West Indies | |
Umbricht et al. | A double-blind placebocontrolled study of the antidepressant effects of the mGlu2 negative allosteric modulator RG1578 in patients with inadequate response to antidepressant therapy | |
Ruane‐O’Hora et al. | Effect of clazosentan, a selective endothelin A receptor antagonist, and tezosentan, a dual endothelin A/B antagonist, on pulsatile shear stress induced constriction of the iliac in the anaesthetized pig | |
Grotsch | Flupentixol/olanzapine/sulpiride/thioridazine | |
Mangoni | Check for The Impact of Ageing on Pharmacokinetics Arduino A. Mangoni and Elzbieta A. Jarmuzewska | |
Pathak et al. | Comparative study on xylazine, bupivacaine and buprenorphine with ketamine as lumbosacral spinal analgesia in uremic buffalo calves | |
Werremeyer | Retrospective review of a case of serotonin syndrome after discontinuation of risperidone: Was withdrawal neuroleptic malignant syndrome missed? | |
Singh et al. | Effect of ondansetron on sensory level produced by intrathecal bupivacaine | |
MA38310A1 (en) | Combination drug comprising phenylephrine and paracetamol | |
Pradelli et al. | Losartan: il valore clinico ed economico |